Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00421811 · ClinicalTrials.gov registry record · Phase 1

A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan

A Phase 1 study of Neoplasms, sponsored by Adherex Technologies.

Completed
Registry status
Phase 1
Development phase
56
Enrollment target
7
Study locations

NCT00421811: Completed Phase 1 study of Neoplasms, sponsored by Adherex Technologies.

NCT00421811 is a Phase 1 study of Neoplasms that has completed, run by Adherex Technologies. The registered enrollment target is 56 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00421811, a Phase 1 study of Neoplasms, has completed, sponsored by Adherex Technologies.

COMPLETED
Registry status
Phase 1
Development phase
56 participants
Enrollment target
7
Study locations

Study Summary

N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 with Normothermic Isolated Limb Infusion of Melphalan in subjects with locally advanced malignant melanoma.

Conditions Studied

Neoplasms

Interventions

  • DRUG melphalan
  • DRUG ADH-1

Study Locations (7)

Florida

  • University of Florida College of Medicine - Gainesville
  • H. Lee Moffitt Cancer Center - Tampa

Colorado

  • University of Colorado, Denver - Aurora

North Carolina

  • Duke University Medical Center - Durham

Pennsylvania

  • Lehigh Valley Hospital - Allentown

Texas

  • MD Anderson Cancer Center - Houston

Utah

  • Intermountain Medical Center - Murray

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2007-04
Est. Completion 2009-03
Phase Phase 1
Adherex Technologies

6 total trials

What the finished NCT00421811 record still lists

NCT00421811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which melphalan is the first listed.

NCT00421811 lists 7 locations in 6 states (Florida, Colorado, North Carolina).

Frequently Asked Questions

What is clinical trial NCT00421811 about?

NCT00421811 is a clinical study titled "A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan". N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 with Normothermic Isolated Limb Infusion of Melphalan in subjects with ...

What is the current status of trial NCT00421811?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2007-04. Estimated completion is 2009-03.

What conditions does trial NCT00421811 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT00421811?

The interventions under investigation include: melphalan (DRUG), ADH-1 (DRUG).

Who is sponsoring clinical trial NCT00421811?

This trial is sponsored by Adherex Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00421811 being conducted?

This trial has 7 study locations across Colorado, Florida, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00421811's enrollment target sits among peer trials

56 100th of 158 higher than 59 of 158 other Neoplasms trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02287428 · 56 participants · Phase 1

    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

  • NCT02923011 · 56 participants · Phase 3

    Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas

  • NCT02935283 · 56 participants

    Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders

  • NCT03375866 · 56 participants · NA

    Effects of Mixed Nut Consumption on Satiety and Weight Management

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00421811, the US trial registry maintained by the National Library of Medicine. NCT00421811 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.